Related Experiment Video

Updated: Aug 7, 2026

Methyl-binding DNA capture Sequencing for Patient Tissues
08:40

Methyl-binding DNA capture Sequencing for Patient Tissues

Published on: October 31, 2016

RASSF1A hypermethylation and its inverse correlation with BRAF and/or KRAS mutations in MSI-associated endometrial

Sokbom Kang1, Jae Myun Lee, Eun-Sook Jeon

  • 1Research Institute and Hospital, National Cancer Center, Goyang, Gyeonggi, Korea.

International Journal of Cancer
|April 19, 2006
PubMed

Insights

Hypermethylation of RASSF1A and KRAS/BRAF mutations are key in endometrial cancer (EC) development. RASSF1A promoter hypermethylation is as crucial as KRAS mutations in activating the RAS pathway during EC tumorigenesis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • RASSF1A gene hypermethylation and KRAS/BRAF mutations are implicated in various human cancers.
  • Endometrial carcinoma (EC) pathogenesis involves complex genetic and epigenetic alterations.
  • Understanding these molecular events is crucial for targeted therapies.

Purpose of the Study:

  • To determine the frequency of RASSF1A hypermethylation and KRAS/BRAF mutations in endometrial carcinoma.
  • To investigate the correlation between these alterations and clinicopathological features, including microsatellite instability (MSI).
  • To elucidate the role of RASSF1A hypermethylation and RAS pathway activation in EC tumorigenesis.

Main Methods:

  • Analysis of RASSF1A methylation using methylation-specific PCR in 75 primary ECs and 4 EC cell lines.
  • Detection of KRAS and BRAF mutations via sequencing.
  • Assessment of microsatellite instability (MSI) and hMLH1 methylation status.

Main Results:

  • RASSF1A methylation was found in 33.3% of ECs, significantly associated with MSI and hMLH1 methylation.
  • KRAS mutations occurred in 18.7% and BRAF mutations in 4.0% of ECs.
  • An inverse correlation between RASSF1A methylation and KRAS/BRAF mutations was observed in MSI-negative ECs, suggesting distinct pathway involvement.

Conclusions:

  • RASSF1A promoter hypermethylation plays a significant role in endometrial carcinoma development, comparable to KRAS mutations in activating the RAS pathway.
  • The interplay between RASSF1A methylation, KRAS/BRAF mutations, and MSI status influences EC tumorigenesis.
  • These findings highlight potential therapeutic targets for endometrial cancer.

More Related Videos

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...